Last Updated:
Searching
Create account to add to watchlist!
Create account to add to watchlist!

MedTech Acquisition Corp - MTAC

  • Commons

    $9.93

    -0.20%

    MTAC Vol: 94.9K

  • Warrants

    $0.06

    -0.17%

    MTACW Vol: 31.9K

  • Units

    $9.95

    +0.20%

    MTACU Vol: 200.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 248.2M
Average Volume: 20.2K
52W Range: $8.99 - $10.21
Weekly %: +0.10%
Monthly %: +0.30%
Inst Owners: 85

Info

Target: Searching
Days Since IPO: 654
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of Class A common stock and one-third of one redeemable warrant
Trust Size: 20000000.0M

🕵Stocktwit Mentions

Last10K posted at 2022-08-10T18:18:43Z

$MTAC just filed a 10-Q Quarterly Report with 5 financial statements and 29 disclosures. Access them all or just read their earnings: https://last10k.com/sec-filings/mtac/0001410578-22-002206.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=mtac

Newsfilter posted at 2022-08-10T16:27:35Z

$MTAC Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/216d229b49e560cdea19a9a738e7c66c

StockInvest_us posted at 2022-07-23T08:30:17Z

Signal alert: $MTAC - Overvalued https://stockinvest.us/stock/MTAC?utm_source=stocktwits&utm_medium=autopost&utm_campaign=autopost

Last10K posted at 2022-05-26T21:17:55Z

$MTAC just filed with the SEC a New Agreement, a New Financial Obligation and a Financial Exhibit https://last10k.com/sec-filings/mtac/0001104659-22-065329.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=mtac

risenhoover posted at 2022-05-26T21:05:52Z

$MTAC / MedTech Acquisition files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 MedTech Acqu https://fintel.io/sf/us/mtac?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-05-26T21:05:42Z

$MTAC 📜 MedTech Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits https://quantisnow.com/i/2952673?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-05-26T21:04:53Z

$MTAC Form 8-K: Entry into a Material Definitive Agreement. On May 24, 2022, MedTech Acquisition500,000 to MedTech Acquisition Sponsor the Company would repay the Note out of the proceeds of the trust.. https://newsfilter.io/a/358e015f7020b0fe0a086227b0e75414

InsiderForms posted at 2022-05-16T21:31:25Z

MSD Partners L.P.,has filed Form 13F for Q1 2022.Opened NEW positions in $BLEU $BLEUR $BLEUW $FB $MTAC $MTACW $PTON $UP

Last10K posted at 2022-05-11T20:20:04Z

$MTAC just filed a 10-Q Quarterly Report with 35 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/mtac/0001410578-22-001311.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=mtac

Quantisnow posted at 2022-05-11T20:08:15Z

$MTAC 📜 SEC Form 10-Q filed by MedTech Acquisition Corporation https://quantisnow.com/i/2870299?utm_source=stocktwits 45 seconds delayed.

risenhoover posted at 2022-05-11T20:07:55Z

$MTAC / MedTech Acquisition files form 10-Q https://fintel.io/sf/us/mtac?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Newsfilter posted at 2022-05-11T20:07:29Z

$MTAC Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/54ced6078f8dc626bf3a8d96bdaf1e11

Fullratio posted at 2022-04-05T15:40:00Z

Financial Services sector stocks with high EPS growth in Q4 2021 (TTM): $IGAC $MTAC $HERA

ChartMill posted at 2022-03-31T18:42:00Z

In the last month $MTAC has a been trading in the 8.99 - 10.21 range, which is quite wide. https://www.chartmill.com/stock/quote/MTAC/technical-analysis?key=ee94d6e7-3d38-4d68-8743-7d32dcbb8e13&utm_source=stocktwits&utm_medium=TA&utm_content=MTAC&utm_campaign=social_tracking

tickeron posted at 2022-03-11T17:42:59Z

Is this good for your portfolio? $MTAC in -2.39% Downtrend, sliding for three consecutive days on March 10, 2022. View odds for this and other indicators: https://srnk.us/go/3485621

stocks_n_blondes posted at 2022-03-11T16:13:01Z

$MTAC what a bummer was hoping to take the $10.00 cash now. When is expiration?

Newsfilter posted at 2022-03-11T16:00:43Z

$MTAC Surgical Robot Maker Memic Terminates SPAC Merger https://newsfilter.io/a/f7e78a25390d967b9d7002cb05c53854

Billionaireclubcollc posted at 2022-03-11T15:52:54Z

( $MTAC) – Surgical Robot Maker Memic Terminates SPAC Merger https://www.billionaireclubcollc.com/mtac-surgical-robot-maker-memic-terminates-spac-merger/

stocks_n_blondes posted at 2022-03-11T15:49:30Z

$MTAC $MOTV $FMAC redeem redeem redeem. Spacs are death traps. The greedy sponsors, founders and PIPE investors dump their shares as soon as despac happens. Its all a scam.

healthcareguru posted at 2022-03-11T03:21:35Z

$MTAC $1

briefingcom posted at 2022-03-10T15:15:22Z

$MTAC and Memic Innovative Surgery Ltd. mutually agree to terminate business combination https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220310081320MTAC&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page

ChartMill posted at 2022-03-10T13:38:00Z

$MTAC: MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Comb ... https://www.chartmill.com/news/MTAC/globenews-2022-3-10-medtech-acquisition-corporation-and-memic-innovative-surgery-ltd-mutually-agree-to-terminate-business-combination?utm_source=stocktwits&utm_medium=pressRelease&utm_content=MTAC&utm_campaign=social_tracking

healthcareguru posted at 2022-03-10T13:33:58Z

$MTAC 👎

healthcareguru posted at 2022-03-10T13:31:51Z

$MTAC $MTACU Game Over…$1 PT. 😂😂🤦‍♂️🤦‍♂️👎👎 $XBI $IWM $XLV

Stonkmoon posted at 2022-03-10T13:15:54Z

$MTAC 2022-03-10 08:11 ET MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination MedTech Acquisition Corporation https://stonkmoon.com/news/MTAC/bbd9a22455ea0489bd15f5667bbd46c4

STCKPRO posted at 2022-03-10T13:15:37Z

$MTAC NEW ARTICLE : MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination https://www.stck.pro/news/MTAC/24165860

fla posted at 2022-03-10T13:13:28Z

$MTAC [15s. delayed]: Issued Press Release on March 10, 08:11:00: MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutual https://s.flashalert.me/Z3JVqN

Quantisnow posted at 2022-03-10T13:12:23Z

$MTAC 📰 MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination https://quantisnow.com/i/2553101?utm_source=stocktwits 45 seconds delayed.

Stock_Titan posted at 2022-03-10T13:11:47Z

$MTAC MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination https://www.stocktitan.net/news/MTAC/med-tech-acquisition-corporation-and-memic-innovative-surgery-ltd-05jdw0ix297z.html

Newsfilter posted at 2022-03-10T13:11:39Z

$MTAC MedTech Acquisition and Memic Innovative Surgery Mutually Agree to Terminate Business Combination https://newsfilter.io/a/8c768b2c6019a838aa51c4e83e261e7e

Management

Officers, Directors and Director Nominees,” “Management — Conflicts of Interest” and “Certain Relationships and Related Party Transactions.” Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests. We have not adopted a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into an initial business combination with a target business that is affiliated with our sponsor, our directors or officers. We do not have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours. The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently, our directors’ and officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our stockholders’ best interest. If this were the case, it would be a breach of their fiduciary duties to us as a matter of Delaware law and we or our stockholders might have a claim against such individuals for infringing on our stockholders’ rights. However, we might not ultimately be successful in any claim we may make against them for such reason. 45 We may engage in an initial business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, officers, directors or existing holders that may raise potential conflicts of interest. In light of the involvement of our sponsor, officers and directors with other entities, we may decide to acquire one or more businesses affiliated with our sponsor, officers or directors. Our directors also serve as officers and board members for other entities, including, without limitation, those described under the section of this prospectus entitled “Management — Conflicts of Interest.” Such entities may compete with us for business combination opportunities. Our sponsor, officers and directors are not currently aware of any specific opportunities for us to complete our initial business combination with any entities with which they are affiliated, and there have been no substantive discussions concerning an initial business combination with any such entity or entities. Although we will not be specifically focusing on, or targeting, any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our criteria for an initial business combination as set forth in the section of this prospectus entitled “Proposed Business — Selection of a Target Business and Structuring of our Initial Business Combination” and such transaction was approved by a majority of our disinterested directors. Despite our agreement to obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions, regarding the fairness to the Company and our stockholders from a financial point of view of an initial business combination with one or more domestic or international businesses affiliated with our officers, directors or existing holders, potential conflicts of interest still may exist and, as a result, the terms of the initial business combination may not be as advantageous to our public stockholders as they would be absent any conflicts of interest. These risks may become more acute as the 24-month deadline for the completion of our initial business combination. Since our sponsor, officers and directors will lose their entire investment in us if our initial business combination is not completed (except with respect to any public shares the may hold), a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination. In September 2020, our sponsor purchased 5,750,000 founder shares, 750,000 of which are subject to forfeiture if the underwriters’ over-allotment option is not exercised. The number of founder shares issued was determined based on the expectation that such founder shares would represent 20% of the outstanding shares after this offering. The founder shares will be worthless if we do not complete an initial business combination. In addition, our sponsor has committed to purchase an aggregate of 4,000,000 (or 4,400,000 if the underwriters’ over-allotment option is exercised in full) private placement warrants, each exercisable for one share of our Class A common stock at $11.50 per share, for a purchase price of $6,000,000 (or $6,600,000 if the underwriters’ over-allotment option is exercised in full), or $1.50 per warrant, that will also be worthless if we do not complete an initial business combination. Holders of founder shares have agreed (A) to vote any shares owned by them in favor of any proposed initial business combination and (B) not to redeem any founder shares in connection with a stockholder vote to approve a proposed initial business combination or in connection with a stockholder vote to approve an amendment to our amended and restated certificate of incorporation. In addition, we may obtain loans from our sponsor, affiliates of our sponsor or an officer or director. The personal and financial interests of our officers and directors may influence their motivation in identifying and selecting a target business combination, completing an initial business combination and influencing the operation of the business following the initial business combination. We may issue notes or other debt securities, or otherwise incur substantial debt, to complete an initial business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our stockholders’ investment in us. Although we have no commitments as of the date of this prospectus to issue any notes or other debt securities, or to otherwise incur outstanding debt following this offering, we may choose to incur substantial debt to complete our initial business combination. We have agreed that we will not incur any indebtedness unless we have obtained from the lender a waiver of any right, title, interest or claim of any kind in or to the monies held in the trust account. As such, no issuance of debt will affect the per-share amount available for redemption from the trust account. Nevertheless, the incurrence of debt could have a variety of negative effects, including: 46 ·default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; ·acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; ·our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; ·our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; ·our inability to pay dividends on our common stock; ·using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes; ·limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; ·increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; ·limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and ·other disadvantages compared to our competitors who have less debt. We may be able to complete only one business combination with the proceeds of this offering and the sale of the private placement warrants, which will cause us to be solely dependent on a single business, which may have a limited number of products or services and limited operating activities. This lack of diversification may negatively impact our operating results and profitability. Of the net proceeds from this offering and the sale of the private placement warrants, $200,000,000 (or $230,000,000 if the underwriters’ over-allotment option is exercised in full) will be available to complete our initial business combination and pay related fees and expenses (which includes up to $7,000,000, or up to $8,050,000 if the over-allotment option is exercised in full, for the payment of deferred underwriting commissions being held in the trust account). We may effectuate our initial business combination with a single target business or multiple target businesses simultaneously or within a short period of time. However, we may not be able to effectuate our initial business combination with more than one target business because of various factors, including the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the SEC that present operating results and the financial condition of several target businesses as if they had been operated on a combined basis. By completing our initial business combination with only a single entity, our lack of diversification may subject us to numerous economic, competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit from the possible spreading of risks or offsetting of losses, unlike other entities which may have the resources to complete several business combinations in different industries or different areas of a single industry. Accordingly, the prospects for our success may be: · solely dependent upon the performance of a single business, property or asset, or · dependent upon the development or market acceptance of a single or limited number of products, processes or services. This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to our initial business combination. 47 We may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability. If we determine to simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make it more difficult for us, and delay our ability, to complete our initial business combination. We do not, however, intend to purchase multiple businesses in unrelated industries in conjunction with our initial business combination. With multiple business combinations, we could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations and services or products of the acquired companies in a single operating business. If we are unable to adequately address these risks, it could negatively impact our profitability and results of operations. We may attempt to complete our initial business combination with a private company about which little information is available, which may result in an initial business combination with a company that is not as profitable as we suspected, if at all. In pursuing our initial business combination strategy, we may seek to effectuate our initial business combination with a privately-held company. Very little public information generally exists about private companies, and we could be required to make our decision on whether to pursue a potential initial business combination on the basis of limited information, which may result in an initial business combination with a company that is not as profitable as we suspected, if at all. Our management may not be able to maintain control of a target business after our initial business combination. We may structure an initial business combination so that the post-transaction company in which our public stockholders own shares will own less than 100% of the equity interests or assets of a target business, but we will only complete such business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for us not to be required to register as an investment company under the Investment Company Act. We will not consider any transaction that does not meet such criteria. Even if the post-transaction company owns 50% or more of the voting securities of the target, our stockholders prior to the initial business combination may collectively own a minority interest in the post business combination company, depending on valuations ascribed to the target and us in the initial business combination. For example, we could pursue a transaction in which we issue a substantial number of new shares of Class A common stock in exchange for all of the outstanding capital stock of a target. In this case, we would acquire a 100% interest in the target. However, as a result of the issuance of a substantial number of new shares of common stock, our stockholders immediately prior to such transaction could own less than a majority of our outstanding shares of common stock subsequent to such transaction. In addition, other minority stockholders may subsequently combine their holdings resulting in a single person or group obtaining a larger share of our stock than we initially acquired. Accordingly, this may make it more likely that our management will not be able to maintain our control of the target business. We cannot provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business. We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete an initial business combination with which a substantial majority of our stockholders do not agree. Our amended and restated certificate of incorporation will not provide a specified maximum redemption threshold, except that we will only redeem our public shares so long as (after such redemption) our net tangible assets will be at least $5,000,001 either immediately prior to or upon consummation of our initial business combination and after payment of deferred underwriters’ fees and commissions (such that we are not subject to the SEC’s “penny stock” rules) or any greater net tangible asset or cash requirement that may be contained in the agreement relating to our initial business combination. As a result, we may be able to complete our initial business combination even though a substantial majority of our public stockholders do not agree with the transaction and have redeemed their shares or, if we seek stockholder approval of our initial business combination and do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, have entered into privately-negotiated agreements to sell their shares to our sponsor, officers, directors, advisors or their affiliates. In the event the aggregate cash consideration we would be required to pay for all shares of Class A common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, all shares of Class A common stock submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate business combination. 48 In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and other governing instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated certificate of incorporation or governing instruments in a manner that will make it easier for us to complete our initial business combination that our stockholders may not support. In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and modified governing instruments, including their warrant agreements. For example, blank check companies have amended the definition of business combination, increased redemption thresholds, changed industry focus and extended the time to consummate an initial business combination and, with respect to their warrants, amended their warrant agreements to require the warrants to be exchanged for cash and/or other securities. Amending our amended and restated certificate of incorporation will require the approval of holders of 65% of our common stock, and amending our warrant agreement will require a vote of holders of at least a majority of the public warrants and, solely with respect to any amendment to the terms of the private placement warrants or any provision of our warrant agreement with respect to the private placement warrants, a majority of the number of the then outstanding private placement warrants. In addition, our amended and restated certificate of incorporation will require us to provide our public stockholders with the opportunity to redeem their public shares for cash if we propose an amendment to our amended and restated certificate of incorporation to (A) modify the substance or timing of our obligation to provide for the redemption of our public shares in connection with an initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of this offering or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial business combination activity. To the extent any such amendments would be deemed to fundamentally change the nature of any securities offered through this registration statement, we would register, or seek an exemption from registration for, the affected securities. We cannot assure you that we will not seek to amend our charter or governing instruments or extend the time to consummate an initial business combination in order to effectuate our initial business combination. The provisions of our amended and restated certificate of incorporation that relate to our pre-business combination activity (and

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 102.21%
% of Float Held by Institutions 102.21%
Number of Institutions Holding Shares 85

Mutual Fund Holders

Holder Shares Date Reported Value % Out
BlackRock Health Sciences Trust II 917284 2022-03-30 8989383 3.6700000000000004
Blackrock Funds-Health Sciences Opportunity Portfolio 831621 2022-02-27 8282945 3.3300000000000005
Merger Fund, The 346875 2022-03-30 3399375 1.39
Blackstone Alternative Multi-Strategy Fund 77005 2022-03-30 754649 0.31
CrossingBridge Pre-Merger SPAC ETF 50000 2022-03-30 490000 0.2
Blackrock Health Sciences Trust 42753 2022-03-30 418979 0.16999999999999998
Pacific Select Fund-Health Sciences Portfolio 35852 2022-03-30 351349 0.13999999999999999
WCM Alternatives Event Driven Fd 28586 2022-03-30 280142 0.11
First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd 22589 2022-03-30 221372 0.09
Thrivent Partner Healthcare Portfolio 22420 2022-03-30 219716 0.09

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2022-08-30 Verition Fund Management LLC 625,928 $6,160,000 0.1% +8.4% 2.003%
2022-08-18 Goldman Sachs Group Inc. 441,359 $4,350,000 0.0% +12.9% 1.412%
2022-08-17 Centiva Capital LP 66,711 $660,000 0.0% +25.0% 0.213%
2022-08-16 Jane Street Group LLC 453,683 $4,470,000 0.0% +3.9% 1.452%
2022-08-16 Centiva Capital LP 66,711 $660,000 0.0% +25.0% 0.213%
2022-08-16 Dark Forest Capital Management LP 285,089 $2,810,000 0.6% +10.5% 0.912%
2022-08-15 Berkley W R Corp 102,476 $1,010,000 0.1% +95.3% 0.328%
2022-08-15 Millennium Management LLC 522,641 $5,150,000 0.0% -21.5% 1.672%
2022-08-15 Linden Advisors LP 53,782 $530,000 0.0% -93.5% 0.172%
2022-08-13 Zeke Capital Advisors LLC 200,000 $1,970,000 0.1% 0 0.640%
2022-08-11 RPO LLC 509,892 $5,020,000 1.3% -2.7% 1.632%
2022-08-11 UBS Group AG 24,817 $240,000 0.0% +20,076.4% 0.079%
2022-08-11 Bank of Montreal Can 777,021 $7,650,000 0.0% 0 2.486%
2022-08-09 Graham Capital Wealth Management LLC 28,511 $280,000 0.2% -7.3% 0.091%
2022-07-15 OTA Financial Group L.P. 32,579 $320,000 0.2% -12.1% 0.104%
2022-06-02 Verition Fund Management LLC 577,382 $5,660,000 0.1% +1,265.8% 1.848%
2022-05-27 Walleye Capital LLC 12,898 $130,000 0.0% +14.2% 0.041%
2022-05-18 Nomura Holdings Inc. 401,757 $3,940,000 0.0% +284.8% 1.286%
2022-05-17 Walleye Capital LLC 12,898 $130,000 0.0% +14.2% 0.041%
2022-05-17 Virtu Financial LLC 21,482 $210,000 0.0% 0 0.069%
2022-05-17 Jane Street Group LLC 436,790 $4,280,000 0.0% +387.1% 1.398%
2022-05-17 Glazer Capital LLC 836,139 $8,189,999 0.2% +35.3% 2.676%
2022-05-17 SkyView Investment Advisors LLC 150,000 $1,470,000 0.3% 0 0.480%
2022-05-17 Gilder Gagnon Howe & Co. LLC 852,080 $8,350,000 0.1% +20.7% 2.727%
2022-05-17 Graham Capital Wealth Management LLC 30,751 $300,000 0.3% +35.6% 0.098%
2022-05-16 Goldman Sachs Group Inc. 390,859 $3,830,000 0.0% +188.3% 1.251%
2022-05-16 Blackstone Inc. 77,005 $760,000 0.0% 0 0.246%
2022-05-16 Berkley W R Corp 52,477 $510,000 0.0% -84.8% 0.168%
2022-05-13 Verition Fund Management LLC 577,382 $5,660,000 0.1% +1,265.8% 1.848%
2022-05-13 Penserra Capital Management LLC 3,168 $31,000 0.0% -42.3% 0.010%
2022-05-13 Basso Capital Management L.P. 250,021 $2,450,000 0.2% 0 0.800%
2022-05-13 Ergoteles LLC 38,940 $380,000 0.0% 0 0.125%
2022-05-13 Cohanzick Management LLC 50,000 $490,000 0.1% 0 0.160%
2022-05-12 Commonwealth of Pennsylvania Public School Empls Retrmt SYS 40,200 $390,000 0.0% -19.6% 0.129%
2022-05-12 Omni Event Management Ltd 1,195,462 $11,720,000 0.7% +171.4% 3.825%
2022-05-11 Landscape Capital Management L.L.C. 99,285 $970,000 0.1% -13.1% 0.318%
2022-05-11 Bracebridge Capital LLC 296,572 $2,910,000 0.2% 0 0.949%
2022-05-10 Karpus Management Inc. 131,000 $1,280,000 0.0% 0 0.419%
2022-04-19 OTA Financial Group L.P. 37,082 $360,000 0.2% 0 0.119%
2022-02-25 AlphaCentric Advisors LLC 25,000 $250,000 0.1% 0 0.080%
2022-02-17 Omni Event Management Ltd 440,454 $4,350,000 0.2% 0 1.409%
2022-02-15 Graham Capital Wealth Management LLC 22,679 $230,000 0.2% 0 0.073%
2022-02-15 Starboard Value LP 298,368 $2,950,000 0.0% -20.4% 0.955%
2022-02-14 Glazer Capital LLC 617,882 $6,110,000 0.1% -12.3% 1.977%
2022-02-14 Whitebox Advisors LLC 52,604 $520,000 0.0% -5.7% 0.168%
2022-02-10 Iron Park Capital Partners LP 55,117 $550,000 0.4% 0 0.176%
2022-02-10 Timelo Investment Management Inc. 50,000 $490,000 0.3% 0 0.160%
2022-02-08 RPO LLC 133,984 $1,320,000 0.4% 0 0.429%
2022-02-01 Landscape Capital Management L.L.C. 114,243 $1,130,000 0.2% -22.0% 0.366%
2022-01-31 CWM LLC 5,000 $49,000 0.0% 0 0.016%
2022-01-26 K.J. Harrison & Partners Inc 35,000 $350,000 0.0% -56.3% 0.112%
2021-11-16 Schonfeld Strategic Advisors LLC 55,000 $550,000 0.0% +71.7% 0.176%
2021-11-16 Verition Fund Management LLC 42,273 $420,000 0.0% -86.3% 0.135%
2021-11-16 Whitebox Advisors LLC 55,804 $550,000 0.0% +38.5% 0.179%
2021-11-16 CNH Partners LLC 122,230 $1,210,000 0.0% -7.6% 0.391%
2021-11-16 CVI Holdings LLC 281,040 $2,790,000 0.2% +12.4% 0.899%
2021-11-15 Deerfield Management Company L.P. Series C 999,999 $9,930,000 0.2% 0 3.200%
2021-11-15 Ancora Advisors LLC 5,100 $51,000 0.0% 0 0.016%
2021-11-15 Polar Asset Management Partners Inc. 392,808 $3,900,000 0.0% -41.8% 1.257%
2021-11-15 Berkley W R Corp 346,185 $3,440,000 0.2% 0 1.108%
2021-11-15 Marshall Wace LLP 828,955 $8,230,000 0.0% +1.6% 2.653%
2021-11-15 Omni Partners US LLC 466,196 $4,630,000 0.2% +111.0% 1.492%
2021-11-15 TIG Advisors LLC 23,238 $230,000 0.0% -5.0% 0.074%
2021-11-15 Glazer Capital LLC 704,634 $7,000,000 0.1% +1,192.5% 2.255%
2021-11-15 Dark Forest Capital Management LP 13,662 $140,000 0.0% 0 0.044%
2021-11-12 Starboard Value LP 375,000 $3,720,000 0.1% +150.0% 1.200%
2021-11-12 Periscope Capital Inc. 107,000 $1,060,000 0.0% 0 0.342%
2021-11-12 Weiss Asset Management LP 194,351 $1,930,000 0.0% 0 0.622%
2021-11-12 Hsbc Holdings PLC 534,051 $5,280,000 0.0% +78.0% 1.709%
2021-11-12 Crestline Management LP 53,850 $540,000 0.1% 0 0.172%
2021-11-12 Magnetar Financial LLC 1,743,417 $17,310,000 0.2% 0 5.579%
2021-11-12 CI Investments Inc. 19,400 $190,000 0.0% 0 0.062%
2021-11-10 Goldman Sachs Group Inc. 135,580 $1,350,000 0.0% -21.5% 0.434%
2021-11-10 Creative Planning 25,000 $250,000 0.0% 0 0.080%
2021-11-09 Basso Capital Management L.P. 58,718 $580,000 0.1% +61.6% 0.188%
2021-11-05 K.J. Harrison & Partners Inc 80,000 $800,000 0.1% -42.9% 0.256%
2021-10-28 Mizuho Securities USA LLC 36,490 $360,000 0.0% 0 0.117%
2021-10-25 Zweig DiMenna Associates LLC 90,000 $890,000 0.1% 0 0.288%
2021-08-25 Marshall Wace LLP 816,086 $7,970,000 0.0% +14.0% 2.611%
2021-08-17 Citadel Advisors LLC 562,323 $5,490,000 0.0% +0.2% 1.799%
2021-08-16 CNH Partners LLC 132,230 $1,290,000 0.0% +105.0% 0.423%
2021-08-16 Schonfeld Strategic Advisors LLC 32,028 $310,000 0.0% +77.7% 0.102%
2021-08-16 Maven Securities LTD 80,681 $790,000 0.0% +61.4% 0.258%
2021-08-16 Goldman Sachs Group Inc. 172,680 $1,680,000 0.0% +9.5% 0.553%
2021-08-16 Marshall Wace LLP 816,086 $7,970,000 0.0% +14.0% 2.611%
2021-08-13 Basso Capital Management L.P. 36,343 $350,000 0.0% 0 0.116%
2021-08-13 Glazer Capital LLC 54,516 $530,000 0.0% 0 0.174%
2021-08-13 MYDA Advisors LLC 403,070 $3,910,000 1.0% +98.5% 1.290%
2021-08-13 Geode Capital Management LLC 18,606 $180,000 0.0% +7.8% 0.060%
2021-08-12 Commonwealth of Pennsylvania Public School Empls Retrmt SYS 50,000 $490,000 0.0% 0 0.160%
2021-08-11 Arena Capital Advisors LLC CA 4,182 $41,000 0.0% 0 0.013%
2021-08-11 Picton Mahoney Asset Management 224,997 $2,180,000 0.1% 0 0.720%
2021-08-06 Segantii Capital Management Ltd 50,000 $490,000 0.0% 0 0.160%
2021-08-03 Landscape Capital Management L.L.C. 10,505 $100,000 0.0% 0 0.034%
2021-05-18 TENOR CAPITAL MANAGEMENT Co. L.P. 20,000 $190,000 0.0% 0 0.073%
2021-05-18 Point72 Asset Management L.P. 200,000 $1,930,000 0.0% 0 0.727%
2021-05-18 Fir Tree Capital Management LP 125,000 $1,210,000 0.0% 0 0.455%
2021-05-18 Verition Fund Management LLC 308,627 $2,980,000 0.0% 0 1.122%
2021-05-18 Berkley W R Corp 24,846 $240,000 0.0% 0 0.090%
2021-05-18 Tudor Investment Corp Et Al 401,403 $3,880,000 0.1% 0 1.460%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2022-08-10 https://www.sec.gov/Archives/edgar/data/1826667/000141057822002206/mtac-20220630x10q.htm
8-K FORM 8-K 2022-05-26 https://www.sec.gov/Archives/edgar/data/1826667/000110465922065329/tm2216928d1_8k.htm
10-Q 10-Q 2022-05-11 https://www.sec.gov/Archives/edgar/data/1826667/000141057822001311/mtac-20220331x10q.htm
8-K FORM 8-K 2022-03-10 https://www.sec.gov/Archives/edgar/data/1826667/000110465922032238/tm228774d1_8k.htm
8-K FORM 8-K 2022-03-08 https://www.sec.gov/Archives/edgar/data/1826667/000110465922031154/tm228615d1_8k.htm
10-K 10-K 2022-03-03 https://www.sec.gov/Archives/edgar/data/1826667/000141057822000252/mtac-20211231x10k.htm
425 425 2022-02-23 https://www.sec.gov/Archives/edgar/data/1826667/000110465922026157/tm227498d1_8k.htm
8-K FORM 8-K 2022-02-23 https://www.sec.gov/Archives/edgar/data/1826667/000110465922026153/tm227498d1_8k.htm
SC 13G/A SC 13G/A 2022-02-14 https://www.sec.gov/Archives/edgar/data/1826667/000090571822000358/medtech_13gam1dec32021.htm
DEFM14A DEFM14A 2022-02-14 https://www.sec.gov/Archives/edgar/data/1826667/000182912622003601/medtech_def14a.htm
DEF 14A DEF 14A 2022-02-14 https://www.sec.gov/Archives/edgar/data/1826667/000182912622003571/medtech_def14a.htm
SC 13G/A SCHEDULE 13G/A, #1 2022-02-14 https://www.sec.gov/Archives/edgar/data/1826667/000089914022000277/h50484181.htm
SC 13G 2022-02-08 https://www.sec.gov/Archives/edgar/data/1826667/000083423722008456/us58507n1054_020822.txt
SC 13G/A SEC SCHEDULE 13G 2022-02-04 https://www.sec.gov/Archives/edgar/data/1826667/000167885822000182/SEC13G_Filing.htm
8-K FORM 8-K 2022-01-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465922009058/tm224797d1_8k.htm
SC 13G/A SC 13G/A 2022-01-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465922008704/tm222458d51_sc13ga.htm
425 425 2022-01-06 https://www.sec.gov/Archives/edgar/data/1826667/000110465922001753/tm221955d1_425.htm
8-K FORM 8-K 2021-12-30 https://www.sec.gov/Archives/edgar/data/1826667/000110465921154806/tm2136614d1_8k.htm
10-Q/A 10-Q/A 2021-12-13 https://www.sec.gov/Archives/edgar/data/1826667/000141057821000527/mtac-20210930x10qa.htm
10-K/A 10-K/A 2021-12-13 https://www.sec.gov/Archives/edgar/data/1826667/000141057821000525/mtac-20201231x10ka.htm
8-K FORM 8-K 2021-12-10 https://www.sec.gov/Archives/edgar/data/1826667/000110465921148284/tm2135044d1_8k.htm
10-Q FORM 10-Q 2021-11-12 https://www.sec.gov/Archives/edgar/data/1826667/000110465921138005/mtac-20210930x10q.htm
425 425 2021-09-09 https://www.sec.gov/Archives/edgar/data/1826667/000110465921113968/tm2127235d2_425.htm
425 425 2021-09-09 https://www.sec.gov/Archives/edgar/data/1826667/000110465921113967/tm2127235d1_425.htm
10-Q FORM 10-Q 2021-08-16 https://www.sec.gov/Archives/edgar/data/1826667/000110465921106437/mtac-20210630x10q.htm
8-K FORM 8-K 2021-08-13 https://www.sec.gov/Archives/edgar/data/1826667/000110465921104628/tm2124926d1_8k.htm
425 FORM 8-K 2021-08-13 https://www.sec.gov/Archives/edgar/data/1826667/000110465921104629/tm2124926d1_8k.htm
10-Q FORM 10-Q 2021-06-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465921086346/mtac-20210331x10q.htm
10-K/A FORM 10-K/A 2021-06-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465921086342/tm2119866d1_10ka.htm
8-K FORM 8-K 2021-06-03 https://www.sec.gov/Archives/edgar/data/1826667/000110465921076370/tm2118488d1_8k.htm
8-K FORM 8-K 2021-06-02 https://www.sec.gov/Archives/edgar/data/1826667/000110465921075722/tm2118274d1_8k.htm
NT 10-Q NT 10-Q 2021-05-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465921068219/tm2114002d2_nt10q.htm
3 OWNERSHIP DOCUMENT 2021-05-03 https://www.sec.gov/Archives/edgar/data/1826667/000110465921060214/xslF345X02/tm2114998d3_3.xml
3 OWNERSHIP DOCUMENT 2021-05-03 https://www.sec.gov/Archives/edgar/data/1826667/000110465921060212/xslF345X02/tm2114998d2_3.xml
8-K FORM 8-K 2021-05-03 https://www.sec.gov/Archives/edgar/data/1826667/000110465921060208/tm2114998d1_8k.htm
10-K FORM 10-K 2021-03-31 https://www.sec.gov/Archives/edgar/data/1826667/000110465921044719/tm2111165d1_10k.htm
3 OWNERSHIP DOCUMENT 2021-03-22 https://www.sec.gov/Archives/edgar/data/1826667/000110465921039478/xslF345X02/tm2110466-2_3seq1.xml
8-K FORM 8-K 2021-03-22 https://www.sec.gov/Archives/edgar/data/1826667/000110465921039475/tm2110466d1_8k.htm
SC 13G SC 13G 2021-02-12 https://www.sec.gov/Archives/edgar/data/1826667/000110465921022028/tm216607-1_sc13g.htm
SC 13G SCHEDULE 13G 2021-02-12 https://www.sec.gov/Archives/edgar/data/1826667/000110465921020865/tm215944d13_sc13g.htm
8-K FORM 8-K 2021-02-05 https://www.sec.gov/Archives/edgar/data/1826667/000110465921012973/tm215544d1_8k.htm
SC 13G SEC SCHEDULE 13G 2021-02-04 https://www.sec.gov/Archives/edgar/data/1826667/000090221921000138/SEC13G_Filing.htm
SC 13G SC 13G 2021-01-19 https://www.sec.gov/Archives/edgar/data/1826667/000090571821000059/medtech_13gdec182020.htm
SC 13G SCHEDULE 13G 2021-01-12 https://www.sec.gov/Archives/edgar/data/1826667/000089914021000048/h13gmedtech.htm
SC 13G 2021-01-08 https://www.sec.gov/Archives/edgar/data/1826667/000083423721000116/us58507n2045_010821.txt
8-K FORM 8-K 2020-12-30 https://www.sec.gov/Archives/edgar/data/1826667/000110465920140566/tm2039486d1_8k.htm
4 OWNERSHIP DOCUMENT 2020-12-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465920139623/xslF345X03/tm2039407d3_4.xml
4 OWNERSHIP DOCUMENT 2020-12-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465920139622/xslF345X03/tm2039407d2_4.xml
4 OWNERSHIP DOCUMENT 2020-12-28 https://www.sec.gov/Archives/edgar/data/1826667/000110465920139621/xslF345X03/tm2039407d1_4.xml
8-K FORM 8-K 2020-12-23 https://www.sec.gov/Archives/edgar/data/1826667/000110465920139004/tm2039161d1_8k.htm
424B4 424B4 2020-12-21 https://www.sec.gov/Archives/edgar/data/1826667/000110465920138083/tm2034341-5_424b4.htm
EFFECT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/999999999520003567/xslEFFECTX01/primary_doc.xml
S-1MEF S-1MEF 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137066/tm2038866-1_s1mef.htm
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137065/xslF345X02/tm2038870-8_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137063/xslF345X02/tm2038870-7_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137062/xslF345X02/tm2038870-6_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137060/xslF345X02/tm2038870-5_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137059/xslF345X02/tm2038870-4_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137057/xslF345X02/tm2038870-3_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137055/xslF345X02/tm2038870-2_3.xml
3 OWNERSHIP DOCUMENT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000110465920137053/xslF345X02/tm2038870-1_3.xml
CERT 2020-12-17 https://www.sec.gov/Archives/edgar/data/1826667/000135445720000803/8A_Cert_MTAC.pdf
8-A12B 8-A12B 2020-12-16 https://www.sec.gov/Archives/edgar/data/1826667/000110465920136193/tm2034341d8_8a12b.htm
S-1/A S-1/A 2020-12-09 https://www.sec.gov/Archives/edgar/data/1826667/000110465920133725/tm2034341-3_s1a.htm
S-1 FORM S-1 2020-11-30 https://www.sec.gov/Archives/edgar/data/1826667/000110465920130568/tm2034341d2_s-1.htm
DRS 2020-10-29 https://www.sec.gov/Archives/edgar/data/1826667/000110465920119056/filename1.htm